文献速递痛风与晶体性关节病

降尿酸药物临床疗效与安全性的定量评价:文献聚合数据的模型分析

Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data.
PubMed 文献 · Semin Arthritis Rheum · 2025-08-05

该研究基于PubMed、Embase和Cochrane图书馆建库至2024年5月26日的临床试验,采用模型引导的荟萃分析(MBMA)定量评估九种降尿酸药物的疗效与安全性。研究纳入49项研究共10591名受试者,比较黄嘌呤氧化酶抑制剂(XOI)、URAT1抑制剂和尿酸酶三类药物在不同剂量、剂型及人群中的降尿酸效果、痛风发作率、eGFR变化及不良事件。

要点

  • 治疗3个月后,XOI、URAT1和尿酸酶的尿酸下降幅度分别为35.4%、37.5%和79.6%。
  • XOI和尿酸酶治疗3个月内痛风发作率分别为18.9%和51.2%,1年后降至7.4%和13.3%。
  • XOI和URAT1的降尿酸效果呈剂量反应关系,缓释剂型优于速释剂型,但高剂量与痛风发作率增加相关。

核心结论

  • 该研究对降尿酸药物的疗效和安全性特征进行了全面的定量分析,为优化痛风和高尿酸血症的治疗策略提供了重要证据。

研究设计与样本

  • 研究检索PubMed、Embase和Cochrane图书馆建库至2024年5月26日的降尿酸药物治疗高尿酸血症或痛风的临床试验,采用模型引导的荟萃分析(MBMA)定量分析血尿酸降低率和痛风发作率的时间效应及其影响因素,并进行单臂荟萃分析总结血尿酸低于6 mg/dl的比例、eGFR、不良事件(AEs)、严重不良事件(SAEs)和脱落率,同时按剂量、剂型和人群进行亚组分析。
  • 共纳入49项研究,涉及10591名受试者,评估了九种药物,分为黄嘌呤氧化酶抑制剂(XOI)、URAT1抑制剂和尿酸酶三类。

主要发现

  • 治疗3个月后,XOI、URAT1和尿酸酶的尿酸水平分别下降35.4%、37.5%和79.6%,疗效平台分别在第7周、第10周和立即达到。
  • 干预3个月内,XOI和尿酸酶的痛风发作率分别为18.9%和51.2%;1年后分别降至7.4%和13.3%。
  • 干预1年后eGFR变化:XOI为0.7%,URAT1为-2.5%。
  • 安全性方面,XOI、URAT1和尿酸酶的AEs发生率分别为55.8%、51.8%和92.4%,SAEs分别为4%、2.4%和18.8%;脱落率分别为17%、8%和31%。
  • 亚组分析显示XOI和URAT1的降尿酸效果呈明显剂量反应关系,灵活给药优于固定给药,缓释制剂优于速释制剂,但更高剂量与痛风发作率增加相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantitatively assess and compare the efficacy and safety characteristics of different urate-lowering drugs, focusing on their dosage, formulation, and effects in various populations, in order to support and optimize current urate-lowering treatment strategies. METHODS: Clinical trials on urate-lowering drug treatments for hyperuricemia or gout were retrieved from PubMed, Embase, and Cochrane Library databases from the inception of the database until May 26, 2024. A model-based meta-analysis (MBMA) was conducted to quantitatively analyze the time effects of serum uric acid reduction rates and gout attack rates following urate-lowering drug interventions, along with their influencing factors. Additionally, a single-arm meta-analysis was performed to summarize the proportion of patients achieving serum uric acid levels below 6 mg/dl, estimated glomerular filtration rate (eGFR), adverse events (AEs), serious adverse events (SAEs) and dropout rate. Subgroup analyses were conducted to compare the efficacy and safety characteristics of urate-lowering drugs across different dosages, formulations, and populations. RESULTS: A total of 49 studies involving 10,591 participants were included, assessing nine drugs across three categories: xanthine oxidase inhibitor (XOI), Urate transporter 1 inhibitor (URAT1), and Urate oxidase (URICASE). Results indicated that after three months, uric acid levels decreased by 35.4 %, 37.5 %, and 79.6 % for XOI, URAT1, and URICASE, respectively, with efficacy platforms reached at weeks 7, 10, and immediately. Within three months of intervention, the gout attack rates for XOI and URICASE were 18.9 % and 51.2 %, respectively; after one year, these rates decreased to 7.4 % and 13.3 %. The changes in eGFR after one year of intervention were 0.7 % for XOI and -2.5 % for URAT1. In terms of safety, the incidence rates of AEs were 55.8 %, 51.8 %, and 92.4 % for XOI, URAT1, and URICASE, respectively, while the SAEs were 4 %, 2.4 %, and 18.8 %. Patient compliance was described in terms of dropout rates, which were 17 %, 8 % and 31 % for XOI, URAT1 and URICASE, respectively. Subgroup analyses revealed a clear dose-response relationship for the urate-lowering effects of XOI and URAT1, with flexible dosing showing superior efficacy compared to fixed dosing, and sustained-release formulations outperforming immediate-release formulations. However, higher doses were associated with an increased rate of gout attacks. CONCLUSION: This study provides a comprehensive quantitative analysis of the efficacy and safety characteristics of urate-lowering drugs, offering important evidence for optimizing treatment strategies for gout and hyperuricemia.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cai Z, Lv Y, Liu Y, et al. Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data. Semin Arthritis Rheum. 2025. PMID: 40780110. doi:10.1016/j.semarthrit.2025.152801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。